Q-omics provides the consensus-scored RAB40AL profile across patient tissues and cancer cell-line models. RAB40AL expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RAB40AL is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, RAB40AL RNA expression shows 16,296 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, KIRC, and UVM as cancer lineages where RAB40AL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB40AL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB40AL survival associations across molecular data types. RAB40AL RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB40AL RNA expression–survival associations across cancer types. High RAB40AL expression shows unfavorable associations in KICH, KIRC and UVM, but favorable associations in SKCM, UCS and SCLC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for RAB40AL RNA expression.
This table summarizes RAB40AL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RAB40AL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB40AL shows lower tumor expression in THCA and higher tumor expression in KIRC, STAD, BLCA, HNSC and LUSC. The KIRC box plot shows higher RAB40AL RNA expression in tumor versus normal tissue (log2 FC = +0.060, t-test p < 0.001).
This table shows molecular features associated with RAB40AL in patient tissues and cancer cell lines. In patient samples, RAB40AL shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB40AL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
